Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2017-03-24 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a 'Company release No 13/2017' dated March 24, 2017. It announces that ALK's partner, Torii, has submitted a registration application to the Japanese Ministry of Health, Labour and Welfare for expanding the use of a drug (MITICURE™) to include paediatric patients. This is a specific announcement regarding regulatory action (submission for approval) and clinical trial results related to a product, but it is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a general regulatory filing (RNS). It details a specific legal/regulatory step concerning product development and approval. This fits best under 'Legal Proceedings Report' (LTR) if interpreted broadly as regulatory action/submission, or potentially 'Regulatory Filings' (RNS) as a general announcement. However, since it details a specific regulatory submission and associated trial data, and does not fit the other specific categories like M&A (TAR) or Capital Change (CAP), it is most appropriately classified as a general Regulatory Filing (RNS) as it is a company press release detailing a regulatory event, which is often the fallback for specific, non-financial, non-governance announcements.
2017-03-24 English
ALKs partner, Torii, indsender registreringsansøgning for tabletvaccinen mod husstøvmideallergi til børn i Japan
Regulatory Filings Classification · 20% confidence The document is a press release announcing a regulatory submission by ALK’s partner to the Japanese Ministry of Health for pediatric expansion of a drug indication. It contains no financial results, management changes, dividends, or other specific report content. It is essentially a business/regulatory announcement that does not fit any more specific category, so it falls into the fallback Regulatory Filings (RNS).
2017-03-24 English
ALKs partner, Torii, indsender registreringsansøgning for tabletvaccinen mod husstøvmideallergi til børn i Japan
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from ALK regarding a regulatory filing submission by their partner, Torii, for a tablet vaccine in Japan. It details the clinical trial results and the nature of the partnership. Since it is a general corporate announcement regarding business operations and regulatory progress that does not fit into specific categories like M&A, Earnings, or Dividends, it is classified as a Regulatory Filing (RNS).
2017-03-24 English
Regulatory Filings 2017
Regulatory Filings
2017-03-23 Danish
Remuneration Information 2017
Remuneration Information Classification · 99% confidence The document is titled "Selskabsmeddelelse nr. 12/2017" (Company Announcement No. 12/2017) and the subject is "Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer" (Reporting of management transactions with ALK-Abelló A/S' B-shares and related securities). It explicitly references Article 19 of the EU Market Abuse Regulation (MAR) and details the awarding of stock options and performance shares to directors/management (Carsten Hellmann, Henrik Jacobi, Søren Niegel, Flemming Pedersen, Helle Skov). This content directly corresponds to the reporting of personal share transactions by company directors and executives, which matches the definition for Director's Dealing (DIRS).
2017-03-23 English
Indberetning af ledelsens transaktioner med ALK-Abelló A/S’ B-aktier og tilknyttede værdipapirer
Director's Dealing Classification · 98% confidence The document is an EU Market Abuse Regulation (MAR) Article 19 notification detailing share-based transactions (granted stock options and performance shares) to directors and management of ALK-Abelló A/S. Such insider share transactions fall under the “Director’s Dealing” category.
2017-03-23 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.